NCT03036098 2026-03-06CheckMate901Bristol-Myers SquibbPhase 3 Active not recruiting1,314 enrolled 23 charts 1 FDA
NCT03390504 2026-02-02THORJanssen Research & Development, LLCPhase 3 Active not recruiting629 enrolled 32 charts 1 FDA
NCT02365597 2026-01-30An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial CancerJanssen Research & Development, LLCPhase 2 Active not recruiting239 enrolled 32 charts 1 FDA
NCT05645692 2026-01-30A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial CancerHoffmann-La RochePhase 2 Active not recruiting204 enrolled
NCT02516241 2026-01-28Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial CancerAstraZenecaPhase 3 Active not recruiting1,126 enrolled 52 charts
NCT04223856 2025-06-13EV-302Astellas Pharma IncPhase 3 Active not recruiting886 enrolled 12 charts 1 FDA